Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
Systematic monitoring of objective parameters provides the most reliable assessment of semaglutide efficacy
Frequently Asked Questions What is the retatrutide triple agonist GLP-1 GIP glucagon mechanism in simple terms
Professional medical evaluation may be appropriate when: Facial hollowing or volume loss is the primary concern Skin laxity is significant There is persistent redness, itching, pain, or a new rash Hair shedding becomes pronounced or continues for several months Dryness is severe despite a simplified routine A changing lesion or pigmented spot requires evaluation The individual is considering injectable or energy-based procedures Consumers should not stop, reduce, or change a prescribed GLP-1 medication because of cosmetic concerns without speaking with the healthcare professional managing their treatment
Studies have also demonstrated changes in other inflammatory markers, including fibrinogen, plasminogen activator inhibitor-1 (PAI-1), and various adhesion molecules involved in vascular inflammation
Penland, D.W
